Akorn, Inc. (NASDAQ:AKRX) Files An 8-K Submission of Matters to a Vote of Security Holders
Item 5.07 Submission of Matters to a Vote of Security Holders.
Akorn, Inc. (the Company) held its 2017 Annual Meeting of
Shareholders on April 27, 2017.The voting results on the
proposals considered at the Annual Meeting are provided below.
Proposal 1: Each of the nominees described in the Companys 2017
proxy statement was elected to serve as a director until the
conclusion of the Companys 2018 annual meeting of shareholders or
until his or her successor is duly elected and qualified, with
the voting results as follows:
| For | Withheld | Broker Non-Votes | ||||
| John N. Kapoor, Ph.D. | 103,760,297 | 740,154 | 9,779,642 | |||
| Kenneth S. Abramowitz | 97,888,140 | 6,612,311 | 9,779,642 | |||
| Adrienne L. Graves, Ph.D. | 103,870,648 | 629,803 | 9,779,642 | |||
| Ronald M. Johnson | 97,923,913 | 6,576,538 | 9,779,642 | |||
| Steven J. Meyer | 97,877,106 | 6,623,345 | 9,779,642 | |||
| Terry Allison Rappuhn | 103,091,999 | 1,408,452 | 9,779,642 | |||
| Brian Tambi | 51,488,794 | 53,011,657 | 9,779,642 | |||
| Alan Weinstein | 100,932,607 | 3,567,844 | 9,779,642 |
Proposal 2: The Companys appointment of BDO USA LLP as its
independent registered public accounting firm for the fiscal year
ending December 31, 2017 was ratified, with the voting results as
follows:
| For | Against | Abstentions | Broker Non-Votes | ||||
| 113,875,698 | 193,670 | 210,725 |
Proposal 3: The Akorn, Inc. 2017 Omnibus Incentive Compensation
Plan was approved with the voting results as follows:
| For | Against | Abstentions | Broker Non-Votes | ||||
| 97,047,429 | 7,355,868 | 97,154 | 9,779,642 |
Proposal 4: The voting results on the frequency for the Companys
future votes on the Companys executive compensation programs
were, on a non-binding advisory basis, as follows:
| 1 Year | 2 Years | 3 Years | Abstentions | |||
| 97,357,987 | 69,016 | 6,829,711 | 243,737 |
Based on the results of the vote, and consistent with the
Board’s recommendation, the Board has determined to hold a
non-binding advisory vote regarding executive compensation every
year until the next required non-binding advisory vote on the
frequency of future votes regarding executive compensation.
Proposal 5: The Companys executive compensation program described
in its 2017 proxy statement was approved on a non-binding
advisory basis, with the voting results as follows:
| For | Against | Abstentions |
Broker Non-Votes |
|||
| 102,859,370 | 1,370,617 | 270,464 | 9,779,642 |
About Akorn, Inc. (NASDAQ:AKRX)
Akorn Inc., together with its subsidiaries, is a specialty pharmaceutical company that develops, manufactures and markets generic and branded prescription pharmaceuticals, as well as private-label over-the-counter (OTC) consumer health products and animal health pharmaceuticals. The Company operates through two segments: Prescription Pharmaceuticals and the Consumer Health. The Prescription Pharmaceuticals segment is engaged in manufacturing and marketing generic and branded prescription pharmaceuticals, including ophthalmics, injectables, oral liquids, otics, topical, inhalants and nasal sprays. The Consumer Health segment is engaged in manufacturing and marketing branded and private-label animal health and OTC products. The Company’s Akorn Consumer Health division (ACH) markets a portfolio of OTC brands and various formulations of private-label OTC pharmaceutical products. Its OTC brand is TheraTears Therapy for Your Eyes, which is a family of therapeutic eye care products. Akorn, Inc. (NASDAQ:AKRX) Recent Trading Information
Akorn, Inc. (NASDAQ:AKRX) closed its last trading session up +0.16 at 33.34 with 9,642,089 shares trading hands.